Product image of Integrilin (Eptifibatide) supplied by GNH India

Integrilin

Active Ingredient:
Eptifibatide
Origin:
EU

Integrilin (Eptifibatide)

Eptifibatide, the active ingredient in Integrilin, is a Glycoprotein IIb/IIIa inhibitor presented as an intravenous solution for intravenous use. It prevents platelet aggregation and is used to reduce cardiac ischemic complications in patients undergoing percutaneous coronary intervention or experiencing acute coronary syndrome.

GNH India supplies Integrilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Glaxosmithkline (Ireland) Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Integrilin (eptifibatide) is employed as an antiplatelet agent in the management of acute coronary syndromes and related interventional procedures.

  • Unstable angina: reduces risk of myocardial infarction and death during percutaneous coronary intervention.
  • Non‑ST‑elevation myocardial infarction (NSTEMI): helps prevent further ischemic events when used with PCI.
  • Acute coronary syndrome (ACS): provides rapid platelet inhibition to limit thrombus formation.
  • Percutaneous coronary intervention (PCI): maintains vessel patency by inhibiting platelet aggregation during the procedure.

How It Works

  • Eptifibatide reversibly binds to the glycoprotein IIb/IIIa receptors on activated platelets, blocking the binding site for fibrinogen and other adhesive molecules. This inhibition prevents cross‑linking of platelets, thereby reducing platelet aggregation and thrombus formation during acute coronary events and interventional procedures.

Side Effects

Eptifibatide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Bleeding at catheter insertion site.
  • Thrombocytopenia.
  • Hypotension.
  • Nausea.
  • Headache.
  • Fever.

Serious or Rare Side Effects

  • Intracranial hemorrhage.
  • Severe allergic reactions (anaphylaxis).
  • Myocardial infarction.
  • Life‑threatening thrombosis.
  • Immune‑mediated thrombocytopenia.
  • Death.

Precautions & Warnings

When using Integrilin, clinicians should consider several safety measures.

  • Renal impairment: adjust infusion rate and monitor renal function.
  • Recent surgery or trauma: assess bleeding risk before administration.
  • Concomitant anticoagulants: increase monitoring for bleeding.
  • History of thrombocytopenia: avoid or use with caution.
  • Pregnancy and lactation: use only if benefits outweigh risks (category unknown).
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Eptifibatide can interact with other agents that affect haemostasis.

Major Interactions (Avoid)

  • Heparin: additive anticoagulant effect, risk of severe bleeding.
  • Other Glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban): combined platelet inhibition may cause life‑threatening hemorrhage.
  • Thrombolytics (alteplase, reteplase): heightened bleeding risk.

Moderate Interactions (Monitor Closely)

  • Warfarin: increased INR, monitor coagulation parameters.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding tendency.
  • CYP450 substrates: minimal interaction but monitor if co‑administered with drugs affecting platelet function.

Frequently Asked Questions

Integrilin contains eptifibatide, an antiplatelet medication used to prevent cardiac ischemic complications in patients with unstable angina, non‑ST‑elevation myocardial infarction, or acute coronary syndrome who are undergoing percutaneous coronary intervention.

Eptifibatide reversibly blocks the glycoprotein IIb/IIIa receptors on activated platelets, preventing fibrinogen from binding and thereby inhibiting platelet aggregation and thrombus formation during acute coronary events.

The dosage and infusion rate of Integrilin are determined by the prescribing clinician based on the patient’s clinical condition, renal function, and procedural requirements. No fixed regimen is provided here.

The pregnancy category for eptifibatide is unknown. It should only be used during pregnancy or lactation if the potential benefits justify the potential risks, and this decision must be made by the treating physician.

Submit an enquiry on the Integrilin product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Integrilin (eptifibatide) is a reversible Glycoprotein IIb/IIIa inhibitor, offering rapid and potent platelet inhibition. Compared with oral agents such as clopidogrel, it provides faster onset and is administered intravenously, making it suitable for acute interventional settings.

Integrilin should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintain the product in its original packaging until ready for use.

Integrilin is supplied as an intravenous solution and is administered by slow IV infusion under continuous clinical monitoring, typically in a cardiac catheterisation laboratory or intensive care setting.

The most serious risks include severe bleeding (including intracranial hemorrhage), life‑threatening thrombocytopenia, allergic reactions such as anaphylaxis, and rare instances of myocardial infarction despite therapy.

Integrilin is contraindicated in patients with active major bleeding, known hypersensitivity to eptifibatide or any component of the formulation, and in those with severe uncontrolled hypertension. Caution is also advised for patients with recent major surgery or a history of severe thrombocytopenia.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Eptifibatide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT